查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566751

腫瘤和癌症藥物市場：按藥物類別和適應症分類：2024-2033 年全球機會分析和產業預測

Oncology-Cancer Drugs Market By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy , Hormonal Therapy), By Indication : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球腫瘤和癌症治療市場價值為1,670億美元，預計2024年至2033年複合年成長率為7.2%，到2033年達到3,352億美元。

腫瘤/癌症藥物包括用於診斷、治療和管理各種類型癌症的專用藥物。這些藥物針對癌細胞或抑制癌症生長和擴散的過程。它包括廣泛的治療藥物方法，從傳統化療到免疫療法和精準醫學等標靶治療。

全球腫瘤學和癌症治療市場受到人口老化、生活方式變化以及環境暴露導致的全球癌症發病率上升的推動，從而推動了對創新療法的需求。患者數量的增加凸顯了需要繼續進行研究和開發工作，以解決不同的癌症類型和未滿足的醫療需求。此外，科學技術領域的進步，特別是分子生物學、基因組學和免疫治療等領域的進步，正在推動抗癌藥物開發的重大進展。專注於驅動癌症進展的特定分子異常的精準醫學策略的興起變得越來越突出。結果是更強大、危害更小的治療方法，推動了腫瘤學和癌症藥物市場的成長。

然而，腫瘤/癌症藥物的開發成本高昂，往往需要大量的臨床前研究、臨床試驗投資，且監管核准有限；然而，與新療法和藥物相關的監管核准預計將為市場參與企業提供一些機會。例如，2023 年 10 月，美國食品藥物管理局(FDA) 在夏季核准了多種針對各種癌症的新療法。 7月，FDA核准了Jemperli（dostarlimab）治療子宮內膜癌的新適應症。

細分概述

腫瘤/癌症藥物市場按藥物類別、適應症和地區細分。依藥物類別分為化療、標靶治療、免疫治療（生技藥品）和荷爾蒙療法。依適應症分為肺癌、胃癌、大腸直腸癌、乳癌、攝護腺癌、肝癌、食道癌、子宮頸癌、腎臟癌、膀胱癌等癌症。按地區分類，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

依藥物類別分類，2023年標靶治療領域佔最大市場佔有率。

有跡象表明，乳癌細分市場在 2023 年佔據了最高的市場佔有率。

按地區分類，北美在 2023 年佔據腫瘤學和癌症治療市場的主導地位。

競爭場景

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章腫瘤/癌症藥物市場：依藥物類別

  • 市場概況
  • 化療
  • 標靶治療
  • 免疫療法（生物療法）
  • 荷爾蒙療法

第5章腫瘤/癌症藥物市場：依適應症分類

  • 市場概況
  • 肺癌
  • 胃癌
  • 大腸直腸癌
  • 乳癌
  • 攝護腺癌
  • 肝癌
  • 食道癌
  • 子宮頸癌
  • 腎癌
  • 膀胱癌
  • 其他癌症

第6章腫瘤/癌症藥物市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國腫瘤/癌症藥物市場
    • 加拿大腫瘤學/癌症藥物市場
    • 墨西哥腫瘤和癌症藥物市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國腫瘤學/癌症藥物市場
    • 法國腫瘤/癌症藥物市場
    • 英國腫瘤學/癌症藥物市場
    • 義大利腫瘤/癌症藥物市場
    • 西班牙腫瘤學/癌症藥物市場
    • 其他歐洲腫瘤/癌症藥物市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國腫瘤/癌症藥物市場
    • 日本腫瘤/癌症治療藥物市場
    • 印度腫瘤/癌症藥物市場
    • 澳洲腫瘤學/癌症藥物市場
    • 韓國腫瘤/癌症藥物市場
    • 其他亞太腫瘤學和癌症藥物市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西腫瘤學/癌症藥物市場
    • 南非腫瘤學/癌症藥物市場
    • 沙烏地阿拉伯的腫瘤和癌症藥物市場
    • 拉丁美洲、中東和非洲的其他腫瘤和癌症藥物市場

第7章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson And Johnson
  • Merck And Co., Inc.
  • Novartis AG
  • Pfizer Inc.
簡介目錄
Product Code: A00042

The global oncology-cancer drugs market was valued at $167.0 billion in 2023, and is projected to reach $335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

The oncology/cancer drugs encompass pharmaceuticals specifically designed to diagnose, treat, and manage various types of cancer. These drugs target cancerous cells or interfere with processes involved in cancer growth and spread. It includes a wide array of therapeutic approaches, ranging from traditional chemotherapy to more targeted therapies like immunotherapy and precision medicine.

The global oncology-cancer drugs market is driven by rise in incidence of cancer globally due to aging population, lifestyle changes, and environmental exposures, which drives the demand for innovative therapies. This growing patient population highlights the need for continuous R&D efforts to address diverse cancer types and unmet medical needs. Furthermore, progress in the field of science and technology, specifically in disciplines such as molecular biology, genomics, and immunotherapy, are propelling substantial advancements in the development of cancer drugs. The rise of precision medicine strategies, which focus on specific molecular abnormalities that fuel cancer progression, is becoming increasingly prominent. This has resulted in the creation of more potent and less harmful therapies, fueling growth in the oncology drugs market.

However, high development costs of oncology drugs are extensive and costly, often requiring significant investments in preclinical studies, clinical trials, and regulatory approvals which limit the adoption of cancer drugs. Nevertheless, approval from regulatory authorities associated with new treatments and drugs is expected to create several opportunities for the market players. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved several new treatments for a range of cancers over the summer. In July, the FDA approved a new indication for Jemperli (dostarlimab) in endometrial cancer.

Segmentation Overview

The oncology-cancer drugs market is segmented into drug class type, indication, and region. Depending on drug class type, the market is categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. According to indication, it is divided into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

Depending on drug class type, the targeted therapy segment held the largest market share in 2023.

By indication, the breast cancer segment accounted for the highest share in the market in 2023.

Region wise, North America dominated the oncology-cancer drugs market in 2023.

Competitive Scenario

The major players operating in the oncology/cancer drugs market include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. Other players in oncology/cancer drugs market includes Bayer AG, Regeneron Pharmaceuticals Inc., and Eli Lilly and Company. These players have adopted several strategies, including partnerships, collaborations, and R&D to maintain their position in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • AbbVie Inc.
    • Amgen
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Class
  • 4.2. Chemotherapy
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Targeted Therapy
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Immunotherapy (Biologic Therapy)
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Hormonal Therapy
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Lung Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Stomach Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Colorectal Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Breast Cancer
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Prostate Cancer
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Liver Cancer
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country
  • 5.8. Esophagus Cancer
    • 5.8.1. Key Market Trends, Growth Factors and Opportunities
    • 5.8.2. Market Size and Forecast, By Region
    • 5.8.3. Market Share Analysis, By Country
  • 5.9. Cervical Cancer
    • 5.9.1. Key Market Trends, Growth Factors and Opportunities
    • 5.9.2. Market Size and Forecast, By Region
    • 5.9.3. Market Share Analysis, By Country
  • 5.10. Kidney Cancer
    • 5.10.1. Key Market Trends, Growth Factors and Opportunities
    • 5.10.2. Market Size and Forecast, By Region
    • 5.10.3. Market Share Analysis, By Country
  • 5.11. Bladder Cancer
    • 5.11.1. Key Market Trends, Growth Factors and Opportunities
    • 5.11.2. Market Size and Forecast, By Region
    • 5.11.3. Market Share Analysis, By Country
  • 5.12. Other Cancers
    • 5.12.1. Key Market Trends, Growth Factors and Opportunities
    • 5.12.2. Market Size and Forecast, By Region
    • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Drug Class
    • 6.2.3. Market Size and Forecast, By Indication
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Oncology-Cancer Drugs Market
      • 6.2.5.1. Market Size and Forecast, By Drug Class
      • 6.2.5.2. Market Size and Forecast, By Indication
    • 6.2.6. Canada Oncology-Cancer Drugs Market
      • 6.2.6.1. Market Size and Forecast, By Drug Class
      • 6.2.6.2. Market Size and Forecast, By Indication
    • 6.2.7. Mexico Oncology-Cancer Drugs Market
      • 6.2.7.1. Market Size and Forecast, By Drug Class
      • 6.2.7.2. Market Size and Forecast, By Indication
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Drug Class
    • 6.3.3. Market Size and Forecast, By Indication
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Oncology-Cancer Drugs Market
      • 6.3.5.1. Market Size and Forecast, By Drug Class
      • 6.3.5.2. Market Size and Forecast, By Indication
    • 6.3.6. France Oncology-Cancer Drugs Market
      • 6.3.6.1. Market Size and Forecast, By Drug Class
      • 6.3.6.2. Market Size and Forecast, By Indication
    • 6.3.7. UK Oncology-Cancer Drugs Market
      • 6.3.7.1. Market Size and Forecast, By Drug Class
      • 6.3.7.2. Market Size and Forecast, By Indication
    • 6.3.8. Italy Oncology-Cancer Drugs Market
      • 6.3.8.1. Market Size and Forecast, By Drug Class
      • 6.3.8.2. Market Size and Forecast, By Indication
    • 6.3.9. Spain Oncology-Cancer Drugs Market
      • 6.3.9.1. Market Size and Forecast, By Drug Class
      • 6.3.9.2. Market Size and Forecast, By Indication
    • 6.3.10. Rest of Europe Oncology-Cancer Drugs Market
      • 6.3.10.1. Market Size and Forecast, By Drug Class
      • 6.3.10.2. Market Size and Forecast, By Indication
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Drug Class
    • 6.4.3. Market Size and Forecast, By Indication
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Oncology-Cancer Drugs Market
      • 6.4.5.1. Market Size and Forecast, By Drug Class
      • 6.4.5.2. Market Size and Forecast, By Indication
    • 6.4.6. Japan Oncology-Cancer Drugs Market
      • 6.4.6.1. Market Size and Forecast, By Drug Class
      • 6.4.6.2. Market Size and Forecast, By Indication
    • 6.4.7. India Oncology-Cancer Drugs Market
      • 6.4.7.1. Market Size and Forecast, By Drug Class
      • 6.4.7.2. Market Size and Forecast, By Indication
    • 6.4.8. Australia Oncology-Cancer Drugs Market
      • 6.4.8.1. Market Size and Forecast, By Drug Class
      • 6.4.8.2. Market Size and Forecast, By Indication
    • 6.4.9. South Korea Oncology-Cancer Drugs Market
      • 6.4.9.1. Market Size and Forecast, By Drug Class
      • 6.4.9.2. Market Size and Forecast, By Indication
    • 6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
      • 6.4.10.1. Market Size and Forecast, By Drug Class
      • 6.4.10.2. Market Size and Forecast, By Indication
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Drug Class
    • 6.5.3. Market Size and Forecast, By Indication
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Oncology-Cancer Drugs Market
      • 6.5.5.1. Market Size and Forecast, By Drug Class
      • 6.5.5.2. Market Size and Forecast, By Indication
    • 6.5.6. South Africa Oncology-Cancer Drugs Market
      • 6.5.6.1. Market Size and Forecast, By Drug Class
      • 6.5.6.2. Market Size and Forecast, By Indication
    • 6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
      • 6.5.7.1. Market Size and Forecast, By Drug Class
      • 6.5.7.2. Market Size and Forecast, By Indication
    • 6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
      • 6.5.8.1. Market Size and Forecast, By Drug Class
      • 6.5.8.2. Market Size and Forecast, By Indication

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. AbbVie Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Amgen
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Astellas Pharma Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. AstraZeneca Plc
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Bristol-Myers Squibb Company
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. F. Hoffmann-La Roche Ltd.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Johnson And Johnson
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Merck And Co., Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Novartis AG
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Pfizer Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments